v3.25.2
Cover - $ / shares
 3 Months Ended
Mar. 31, 2025
May 14, 2025
Document Type 10-Q/A  
Amendment Flag true  
Amendment Description We are filing this Amendment No. 1 on Form 10-Q/A (the “Amendment” or “Form 10-Q/A”) to amend our Quarterly Report Form 10-Q for the three months ended March 31, 2025, which was originally filed with the U.S. Securities and Exchange Commission (“SEC”) on May 14, 2025 (the “Original Form 10-Q”). The purpose of this amendment is to restate our previously issued unaudited condensed consolidated financial statements and related financial information in the Original Form 10-Q. This Amendment also restates our previous conclusion and disclosure with respect to the effectiveness of our internal control over financial reporting.Restatement Background  While preparing the Company’s second quarter 2025 condensed consolidated financial statements, the Company identified an error in the Company’s condensed consolidated financials for the quarter ended Meach 31, 2025 that caused an understatement to liabilities and a corresponding overstatement of equity. The error had no cash impact and no impact on net loss.   Prior to the close of the business combination, on October 2, 2024, PowerUp entered into a Promissory Note Fee Agreement with Sponsor (the “Promissory Note Fee Agreement”). Pursuant to the Promissory Note Fee Agreement, PowerUp and Sponsor agreed that Sponsor took a significant risk on behalf of the Company by entering into the Visiox Promissory Note in exchange for payment of the Original Promissory Note Fee, and that Sponsor should be compensated for that risk despite the termination of the right to receive the Original Promissory Note Fee as a result of the termination of the Visiox BCA. As consideration for the foregoing, the Company agreed to pay Sponsor a modified promissory note fee of $1,000,000 (the “Modified Promissory Note Fee”) upon the successful closing of a Business Combination. At the close of the Business Combination in February, 2025, the $1,000,000 fee was unpaid and Aspire Biopharma Holdings Inc. assumed the obligations. The disclosure was made on the March 31, 2025 financial statements but the corresponding liability and equity entry was not recorded at close of the business combination. This Amendment is being filed to restate the financial statements to reflect the recognition of this liability in the Company’s financial statements.   Items Amended in this Filing   This Form 10-Q/A amends and restates the following items of the Original Form 10-Q:   ● Part I - Item 1. Financial Statements ● Part I -  Item 4. Controls and Procedures. ● Part II - Item 6. Exhibits.   In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the certifications specified in Rule 13a-14 under the Exchange Act from the Company’s Chief Executive Officer and its Chief Financial Officer, dated as of the date hereof, are being filed or furnished, as applicable, with this Form 10-Q/A as Exhibits 31.1, 31.2, 32.1 and 32.2. This Form 10-Q/A also includes an updated signature page.   This Form 10-Q/A includes only those items and exhibits to the Original Form 10-Q that are being amended and restated in connection with the matters described herein, and unaffected items and exhibits are not included herein. This Form 10-Q/A should be read in conjunction with the Original Form 10-Q and our filings with the SEC subsequent to the Original Form 10-Q, together with any amendments to those filings.   Except as otherwise provided, the disclosures in this Form 10-Q/A are made as of the date of the Original Form 10-Q and do not reflect any events that occurred after the date of the Original Form 10-Q or modify or update any other disclosures in the Original Form 10-Q affected by subsequent events. As such, forward-looking statements included in this Form 10-Q/A may represent management’s views as of the date of the Original Form 10-Q and should not be assumed to be accurate as of any date thereafter.    Internal Control Considerations   The Error and the related restatements were the result of a material weakness in the Company’s internal control over financial reporting. As a result, management has concluded that the Company’s disclosure controls and procedures were not effective as of March 31, 2025. See Part I - Item 4. Controls and Procedures, in this Form 10-Q/A for additional information related to this material weakness in internal control over financial reporting and the related remedial measures.    
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2025  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2025  
Current Fiscal Year End Date --12-31  
Entity File Number 001-41293  
Entity Registrant Name Aspire Biopharma Holdings, Inc.  
Entity Central Index Key 0001847345  
Entity Tax Identification Number 33-3467744  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 194 Candelaro Drive, #233  
Entity Address, City or Town Humacao  
Entity Address, Country PR  
Entity Address, Postal Zip Code 00791  
City Area Code (908)  
Local Phone Number 987-3002  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   49,525,970
Entity Listing, Par Value Per Share $ 0.0001  
Common Stock, par value $0.0001 per share [Member]    
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol ASBP  
Security Exchange Name NASDAQ  
Warrants, each exercisable for one share of common stock [Member]    
Title of 12(b) Security Warrants, each exercisable for one share of common stock  
Trading Symbol ASBPW  
Security Exchange Name NASDAQ